Researchers from the Broad Institute of MIT and Harvard and the Dana-Farber Cancer Institute describe a new method that dramatically simplifies an arduous experimental process in early drug discovery.
The acquisition aims to enhance HYTN’s manufacturing processes, and specifically to increasing the yield of tryptamine in psychedelic mushrooms, and grants HYTN exclusive access to Prism’s ...
The Licensed IP, which represents Prism’s material asset, is currently undergoing patent review, and is actively being deployed in connection with the cultivation of psilocybin-containing mushrooms at ...
CAMBRIDGE, MA, February 29, 2016 - In a paper published in Nature Biotechnology, researchers from the Broad Institute of MIT and Harvard and the Dana-Farber Cancer Institute describe a new method that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results